We investigate the correlation of the tissue expressions of NM23-H1, androgen receptor, serum PSA and PAP in patients with prostate cancer and benign prostatic hyperplasia to search for the possible relevance for the prognosis. Seventy-five patients were included to study, of these, 55 were diagnosed with prostate cancer and 20 with benign prostatic hyperplasia. Twenty-eight percent of stage I, 54% of stage II, 33 % of stage III and IV cases show the NM23- H1 expressions. The metastatic and nodal diseases (55%) mostly showed the strong intensity of NM23-H1. The correlations between stages and NM23-H1 expression were not statistically significant. A variable but steady NM23 staining from all different stages was noted. However, no correlations among NM23-H1, AR, PSA, PAP and tumor grading in terms of disease prognosis were seen, except for the moderately differentiated tumors with moderate PSA expression levels which have the statistically significant correlation with increased expression of the NM23-H1. [Turk J Cancer 2009;39(4):136-145]